MedPath

FDA Approves Accord BioPharma's IMULDOSA, a Biosimilar to Stelara, for Inflammatory Conditions

• The FDA has approved IMULDOSA (ustekinumab-srlf), a biosimilar developed by Accord BioPharma, for treating chronic inflammatory conditions.. • IMULDOSA is indicated for conditions including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, expanding treatment options. • This marks Accord BioPharma's second biosimilar approval in the U.S. following HERCESSI, and the fifth ustekinumab biosimilar to gain FDA approval. • A positive opinion from the Committee for Medicinal Products for Human Use supports potential EU marketing authorization for IMULDOSA.

Accord BioPharma announced FDA approval of IMULDOSA (ustekinumab-srlf) on October 14, 2024, a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is indicated for the treatment of chronic inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This approval marks a significant step in expanding treatment options for these conditions.
IMULDOSA is Accord BioPharma’s second FDA-approved biosimilar product in the United States, following the approval of HERCESSI (trastuzumab-strf) in April 2024. It is also the fifth ustekinumab biosimilar to be approved by the FDA, increasing the availability of this treatment option.

European Regulatory Progress

Just days after the FDA approval, on October 17, 2024, IMULDOSA received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). The CHMP recommended that the European Commission grant marketing authorization for IMULDOSA for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn’s disease. This positive opinion brings IMULDOSA closer to receiving a European Commission decision, potentially expanding its availability to patients in Europe.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

European Commission Approves Accord Healthcare's Ustekinumab Biosimilar, Imuldosa

The European Commission has granted marketing authorization for Imuldosa, a biosimilar to Stelara (ustekinumab), for immune-mediated inflammatory diseases.
Imuldosa's approval is based on comprehensive data, including a Phase III trial demonstrating therapeutic equivalence and comparable safety to Stelara in plaque psoriasis patients.

FDA Accepts Dupilumab Application for Chronic Spontaneous Urticaria Treatment

The FDA has accepted the sBLA for dupilumab for treating chronic spontaneous urticaria (CSU) in adults and children aged 12 years and older.
The target action date for potential approval of dupilumab for CSU is set for April 18, 2025, marking a potential first targeted therapy in a decade.

Daratumumab Seeks Approval for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson has submitted applications to the FDA and EMA for subcutaneous daratumumab to treat high-risk smoldering multiple myeloma.
The applications are supported by data from the phase 3 AQUILA study, with initial findings expected at the upcoming ASH meeting.

FDA Approves Accord BioPharma's IMULDOSA (Ustekinumab-srlf) as Biosimilar

Accord BioPharma has received FDA approval for IMULDOSA (Ustekinumab-srlf), a biosimilar to Stelara, used in treating inflammatory diseases.
IMULDOSA is approved for multiple indications, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, offering a cost-effective alternative.

Imuldosa (Ustekinumab-srlf) Receives FDA Approval as Stelara Biosimilar

Imuldosa, a biosimilar to Stelara, has been approved by the FDA for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Developed by Dong-A ST and Meiji Seika Pharma, Imuldosa demonstrated similar pharmacokinetic characteristics, safety, tolerability, and efficacy to Stelara in clinical trials.

FDA Gears Up for Key Approval Decisions in Q4 2024

The FDA is set to decide on dasiglucagon for congenital hyperinsulinism, with a PDUFA date of October 8, potentially benefiting pediatric patients.
Nivolumab-based regimens for resectable NSCLC are under review, supported by Phase 3 data showing a 42% reduction in disease recurrence, with a PDUFA date of October 8.

Bio-Thera Solutions' Ustekinumab Biosimilar BAT2206 Gains Regulatory Acceptance in US and EU

Bio-Thera Solutions announced FDA acceptance of the BLA for BAT2206, a proposed interchangeable biosimilar to Stelara® (ustekinumab), seeking US commercial license.
The EMA has also accepted Bio-Thera's MAA for BAT2206, a biosimilar to Stelara®, marking the first ustekinumab biosimilar from a Chinese company submitted to both agencies.

FDA Approves Pyzchiva (ustekinumab-ttwe), Biosimilar to Stelara, for Inflammatory Conditions

The FDA has approved Pyzchiva (ustekinumab-ttwe) as a biosimilar to Stelara for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Pyzchiva, developed by Samsung Bioepis and commercialized by Sandoz, is expected to launch in the U.S. in February 2025, potentially offering a more affordable treatment option.

EMA Approves First Ustekinumab Biosimilar, Uzpruvo, for Inflammatory Conditions

The European Medicines Agency (EMA) has granted marketing authorization to Uzpruvo, the first biosimilar to Stelara (ustekinumab), potentially expanding patient access through competition.
Uzpruvo is indicated for Crohn's disease, psoriatic arthritis, and plaque psoriasis, offering a cost-effective treatment option for millions of patients with these conditions.

Accord BioPharma's Ustekinumab Biosimilar BLA Accepted by FDA, Launch Expected by May 2025

Accord BioPharma's Biologics License Application (BLA) for DMB-3115, a biosimilar to Janssen's Stelara® (ustekinumab), has been accepted by the US FDA.
DMB-3115 was jointly developed by Dong-A ST and Meiji Seika Pharma, with Intas Pharmaceuticals holding exclusive licensing rights, excluding specific Asian countries.

Reference News

[1]
Accord Biopharma Announces FDA Approval of IMULDOSA (ustekinumab-srlf) | JD Supra
jdsupra.com · Oct 25, 2024

Accord BioPharma's IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA, received FDA approval for chronic inflammatory ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy